[Bronchiolitis obliterans postallogeneic stem cell transplantation: what is new?]

Rev Pneumol Clin. 2011 Sep;67(4):258-66. doi: 10.1016/j.pneumo.2011.06.003. Epub 2011 Aug 6.
[Article in French]

Abstract

Bronchiolitis obliterans (BO) is a severe complication of hematopoietic stem cell transplantation (HSCT). It is considered as a respiratory manifestation of chronic graft-versus-host disease. It is quite similar to the bronchiolitis obliterans after lung transplantation. Classical therapy associates steroids and immunosuppressive drugs, however theses procedure showed a modest efficacy and have an important morbidity. Recent progresses in the physiopathology of BO post-HSCT allow to use new treatments: mTOR inhibitors, immunotherapy, extra-corporeal photochemotherapy, and bronchial anti-inflammatory effects of azithromycin, statins or antileucotriens. This review will focus on the use of these new therapies in BO post-HSCT.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Bronchiolitis Obliterans / etiology*
  • Bronchiolitis Obliterans / physiopathology
  • Bronchiolitis Obliterans / therapy
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Humans
  • Risk Factors